Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentazocine + acetaminophen is an oral combination drug used for the relief of mild to moderate pain. It contains pentazocine, a Schedule IV opioid analgesic with mixed agonist/antagonist properties at opioid receptors, and acetaminophen, a non-opioid analgesic and antipyretic. Pentazocine primarily acts as an agonist at kappa opioid receptors and as a weak antagonist/partial agonist at mu opioid receptors, leading to pain relief while limiting some opioid side effects. Acetaminophen acts centrally to reduce pain and fever, though its exact mechanism is not fully understood. The combination provides additive analgesic effects and is intended for short-term use due to the risk of dependence, hepatotoxicity from acetaminophen overdose, and opioid withdrawal with abrupt cessation. This combination product was marketed under the brand name Talacen but has been discontinued in the United States[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentazocine + acetaminophen.